Five Prime Therapeutics (FPRX) said updated data on its FP-1039 demonstrated an objective response rate of 48% and six-month disease control rate of 81% in patients with malignant pleural mesothelioma.
Patients treated with the drug in the ongoing phase 1b trial showed progression free survival of 7.4 months, the company said, which correlated positively with increasing expression levels of tumoral FGF2. The vast majority of adverse events were grades one or two, the company said, with three dose-limiting toxicities observed at the 20 mg/kg dose.
Five Prime also presented an oral poster discussion featuring data related to its antibody FPA150. The drug “appears to possess both T cell checkpoint blockade activity and enhanced ADCC,” the company said, and it “has the potential to be an effective therapeutic by improving anti-tumor immune responses in cancer patients who may not respond well to PD-1 or PD-L1-targeted agents.”
Five Prime said studies are ongoing to enable an investigational new drug application for the antibody.